

Advances in Monoclonal Antibody Therapy for Moderate to Severe Psoriasis: Targeting TNF, IL-17, And IL-23 Pathways for Optimal Disease Management

José Anthar Ávalos Narváez¹, Kevin Daniel Solís Dittrich¹, María Elisa González Robles², Michelle Jiménez Zaragoza¹, Ricardo Arturo Ovilla Alvarez¹, Mayra Aréchiga López²

¹Universidad autónoma de Aguascalientes. Aguascalientes, Mexico.

²Universidad de Guadalajara. Guadalajara, Jalisco, Mexico.

ABSTRACT

Psoriasis, a chronic immune-mediated dermatological disorder, significantly impacts patients' quality of life, particularly in its moderate to severe forms. The advent of biologic therapies, specifically monoclonal antibodies (mAbs), has revolutionized the treatment landscape. This article provides an in-depth analysis of the efficacy, safety, and mechanistic insights of anti-TNF (e.g., adalimumab, infliximab), anti-IL-17 (e.g., secukinumab, ixekizumab), and anti-IL-23 (e.g., guselkumab, risankizumab) agents in the management of moderate to severe psoriasis. Clinical trials and real-world evidence demonstrate that these biologics achieve substantial improvements in Psoriasis Area and Severity Index (PASI) scores, Dermatology Life Quality Index (DLQI), and long-term remission rates. However, their use is not without risks, including potential adverse effects such as infections, immunogenicity, and rare paradoxical reactions. This review underscores the importance of personalized treatment strategies, considering patient-specific factors such as comorbidities, disease severity, and treatment history. By synthesizing current evidence, this article aims to guide clinicians in optimizing therapeutic outcomes while mitigating risks associated with monoclonal antibody therapy in psoriasis management.

KEYWORDS: Monoclonal antibodies, psoriasis, anti-TNF, anti-IL-17, anti-IL-23, biologic therapy, PASI, DLQI, immunogenicity, personalized medicine.

ARTICLE DETAILS

Published On:
23 May 2025

Available on:
<https://ijmscrs.com/>

INTRODUCTION:

Psoriasis is a chronic, systemic, immune-mediated inflammatory disease characterized by hyperproliferation of keratinocytes, aberrant differentiation, and immune dysregulation, primarily involving the IL-23/Th17 axis. Affecting approximately 2-3% of the global population, moderate to severe psoriasis is associated with significant morbidity, including psoriatic arthritis, cardiovascular comorbidities, and profound psychological distress. Traditional systemic therapies, such as methotrexate and cyclosporine, have been limited by their toxicity profiles and suboptimal efficacy. The emergence of biologic therapies, particularly monoclonal antibodies (mAbs), has transformed the therapeutic paradigm, offering targeted inhibition of key cytokines implicated in psoriasis pathogenesis.^{1,2}

Among these, anti-TNF agents (e.g., adalimumab, infliximab) were the first biologics approved for psoriasis, demonstrating efficacy in reducing inflammation and improving skin clearance. However, their use is often limited by secondary failure and adverse effects, prompting the development of newer agents targeting the IL-23/Th17 pathway. Anti-IL-17 agents (e.g., secukinumab, ixekizumab) and anti-IL-23 agents (e.g., guselkumab, risankizumab) have shown superior efficacy in achieving PASI 90 and PASI 100 responses, with favorable safety profiles. These therapies specifically neutralize IL-17A or inhibit IL-23, a cytokine critical for the differentiation and maintenance of Th17 cells, which play a central role in psoriasis pathogenesis.^{3,4} Despite their clinical benefits, the use of monoclonal antibodies necessitates careful consideration of potential adverse effects, including increased risk of infections,

Advances in Monoclonal Antibody Therapy for Moderate to Severe Psoriasis: Targeting TNF, IL-17, And IL-23 Pathways for Optimal Disease Management

immunogenicity, and rare paradoxical reactions. Furthermore, the high cost of biologics and the need for long-term therapy underscore the importance of identifying predictors of response and optimizing treatment strategies. This article aims to provide a comprehensive review of the current evidence on the use of anti-TNF, anti-IL-17, and anti-IL-23 monoclonal antibodies in moderate to severe psoriasis, highlighting their mechanisms of action, clinical efficacy, safety profiles, and place in therapy. By integrating findings from randomized controlled trials, real-world studies, and expert consensus, this review seeks to inform evidence-based decision-making in the management of this complex and debilitating condition.⁴

Current Advances in the Use of Monoclonal Antibodies (Anti-TNF, Anti-IL-17, and Anti-IL-23) for the Management of Moderate to Severe Psoriasis

The management of moderate to severe psoriasis has undergone a paradigm shift with the advent of biologic therapies, particularly monoclonal antibodies (mAbs) targeting specific cytokines involved in the immunopathogenesis of the disease. These therapies, including anti-tumor necrosis factor (anti-TNF), anti-interleukin-17 (anti-IL-17), and anti-interleukin-23 (anti-IL-23) agents, have demonstrated remarkable efficacy in achieving significant clinical improvement, enhancing patients' quality of life, and addressing the systemic nature of psoriasis. Recent advances in the field have further refined their use, optimizing therapeutic outcomes while minimizing adverse effects. This article explores the latest developments in the application of these monoclonal antibodies, focusing on their mechanisms of action, clinical efficacy, safety profiles, and emerging trends in personalized treatment approaches.⁵

Mechanistic Insights and Therapeutic Targets

Psoriasis is a chronic, immune-mediated inflammatory disorder characterized by dysregulation of the IL-23/Th17 axis, leading to the overproduction of pro-inflammatory cytokines such as TNF, IL-17, and IL-23. These cytokines play pivotal roles in the pathogenesis of psoriasis, driving keratinocyte hyperproliferation, immune cell infiltration, and sustained inflammation. Monoclonal antibodies have been developed to specifically target these cytokines, thereby interrupting the inflammatory cascade at critical points.⁵

Anti-TNF Agents: TNF is a key cytokine involved in the initiation and perpetuation of psoriatic inflammation. Anti-TNF agents such as adalimumab, infliximab, and etanercept were among the first biologics approved for psoriasis. They work by neutralizing TNF, reducing inflammation, and improving skin clearance. However, their long-term use is often limited by secondary loss of efficacy and potential adverse effects, including infections and immunogenicity.⁵

Anti-IL-17 Agents: IL-17A, a cytokine produced by Th17 cells, is a central mediator of psoriatic inflammation. Anti-IL-

17 agents like secukinumab, ixekizumab, and brodalumab have shown superior efficacy in achieving high rates of Psoriasis Area and Severity Index (PASI) 90 and PASI 100 responses.⁶

These agents directly inhibit IL-17A, leading to rapid and sustained improvements in skin lesions and symptoms.

Anti-IL-23 Agents: IL-23 is a master regulator of Th17 cell differentiation and survival. Anti-IL-23 agents such as guselkumab, risankizumab, and tildrakizumab selectively target the p19 subunit of IL-23, effectively suppressing the Th17 pathway. These agents have demonstrated exceptional efficacy, particularly in maintaining long-term remission with less frequent dosing compared to other biologics.⁶

Clinical Efficacy and Real-World Evidence

Recent clinical trials and real-world studies have reinforced the efficacy of monoclonal antibodies in the management of moderate to severe psoriasis. Anti-IL-17 and anti-IL-23 agents, in particular, have set new benchmarks for treatment outcomes. For example, secukinumab and ixekizumab have consistently achieved PASI 90 response rates exceeding 70% in clinical trials, with many patients reaching complete skin clearance (PASI 100). Similarly, guselkumab and risankizumab have demonstrated durable efficacy, with high rates of sustained response over 52 weeks and beyond.⁷

Real-world evidence has further validated the effectiveness of these therapies in diverse patient populations, including those with comorbid conditions such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. These studies have also highlighted the importance of early intervention with biologics to prevent disease progression and improve long-term outcomes.⁷

Safety Profiles and Risk Mitigation

While monoclonal antibodies are generally well-tolerated, their use is associated with potential risks, including infections, immunogenicity, and rare paradoxical reactions. Anti-TNF agents, for instance, carry a higher risk of tuberculosis reactivation and opportunistic infections, necessitating rigorous screening and monitoring. Anti-IL-17 agents have been linked to an increased incidence of candidiasis, while anti-IL-23 agents appear to have a more favorable safety profile with fewer systemic side effects.⁷

Advances in pharmacovigilance and patient stratification have enabled clinicians to identify individuals at higher risk of adverse events and tailor treatment accordingly. Additionally, the development of biosimilars for anti-TNF agents has expanded access to biologic therapy while maintaining comparable efficacy and safety.⁸

Emerging Trends and Future Directions

The field of psoriasis treatment is rapidly evolving, with several promising developments on the horizon. These include:

Personalized Medicine: Advances in biomarker research are paving the way for personalized treatment strategies,

Advances in Monoclonal Antibody Therapy for Moderate to Severe Psoriasis: Targeting TNF, IL-17, And IL-23 Pathways for Optimal Disease Management

enabling clinicians to predict response to specific biologics based on genetic, molecular, and clinical profiles.⁹

Novel Therapeutic Targets: Investigational agents targeting alternative pathways, such as IL-36 and Janus kinase (JAK) inhibitors, are being explored as potential additions to the psoriasis armamentarium.¹⁰

Combination Therapies: The use of biologics in combination with other systemic therapies or phototherapy is being investigated to enhance efficacy and reduce treatment burden.¹¹

Long-Acting Formulations: Research is underway to develop long-acting formulations of monoclonal antibodies, allowing for less frequent dosing and improved patient adherence.¹²

CONCLUSION

The advent of monoclonal antibodies targeting specific cytokines, such as TNF, IL-17, and IL-23, has fundamentally transformed the therapeutic landscape for moderate to severe psoriasis. These biologic agents have demonstrated unparalleled efficacy in achieving significant clinical improvement, including high rates of Psoriasis Area and Severity Index (PASI) 90 and PASI 100 responses, as well as sustained long-term remission. By precisely inhibiting key pathways in the IL-23/Th17 axis, these therapies address the underlying immunopathogenesis of psoriasis, offering patients not only substantial skin clearance but also improvements in quality of life and reductions in systemic inflammation. The success of anti-TNF, anti-IL-17, and anti-IL-23 agents underscores the importance of targeted immunomodulation in managing this chronic, immune-mediated disease.

Despite their remarkable efficacy, the use of monoclonal antibodies is not without challenges. Potential adverse effects, such as infections, immunogenicity, and rare paradoxical reactions, necessitate careful patient selection, rigorous monitoring, and individualized treatment strategies. Advances in pharmacovigilance, biomarker research, and personalized medicine are helping to mitigate these risks, enabling clinicians to optimize therapeutic outcomes while minimizing complications. Furthermore, the development of biosimilars for anti-TNF agents has expanded access to biologic therapies, making these advanced treatments available to a broader patient population.

Looking ahead, the field of psoriasis treatment continues to evolve rapidly, with ongoing research exploring novel therapeutic targets, combination therapies, and long-acting formulations. Emerging agents targeting cytokines such as IL-36 and pathways like JAK-STAT hold promise for further expanding the treatment armamentarium. Additionally, the integration of real-world evidence and patient-reported outcomes is enhancing our understanding of the long-term benefits and risks associated with biologic therapies, guiding more informed clinical decision-making.

In conclusion, monoclonal antibodies have revolutionized the management of moderate to severe psoriasis, offering patients the possibility of achieving clear or almost-clear skin and significantly improving their overall well-being. As our understanding of the immunopathogenesis of psoriasis deepens and new therapeutic innovations emerge, the future of psoriasis treatment lies in personalized, precision medicine. By tailoring therapy to individual patient profiles and leveraging the latest advancements in biologic and biosimilar therapies, clinicians can continue to improve outcomes for patients with this complex and debilitating condition. The ongoing commitment to research, innovation, and patient-centered care ensures that the management of psoriasis will remain at the forefront of dermatologic and immunologic medicine.

REFERENCES

- I. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol.* (2013) 133:377–85. doi: 10.1038/jid.2012.339
- II. Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? *Expert Opin Ther Targets.* (2014) 18:513–25. doi: 10.1517/14728222.2014.889686
- III. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. *J Invest Dermatol.* (2013) 133:17–26. doi: 10.1038/jid.2012.194
- IV. Bergboer JGM, Zeeuwen P, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. *J Invest Dermatol.* (2012) 132:2320–31. doi: 10.1038/jid.2012.167
- V. Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. *J Mol Biol.* (2008) 382:931–41. doi: 10.1016/j.jmb.2008.07.051
- VI. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity.* (2000) 13:715–25. doi: 10.1016/S1074-7613(00)00070-4
- VII. Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. *F1000BiolRep.* (2010) 2:40. doi: 10.3410/B2-40
- VIII. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. *Immunology.* (2012) 135:112–24.

Advances in Monoclonal Antibody Therapy for Moderate to Severe Psoriasis: Targeting TNF, IL-17, And IL-23 Pathways for Optimal Disease Management

- doi: 10.1111/j.1365-2567.2011.03522.x
- IX. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. *J Immunol.*(2006) 176:1908–15. doi: 10.4049/jimmunol.176.3.1908
- X. Smits HH, van Beelen AJ, Hessle C, Westland R, de Jong E, Soeteman E, et al. Commensal gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. *Eur J Immunol.*(2004) 34:1371–80. doi: 10.1002/eji.200324815
- XI. Liu W, Ouyang X, Yang J, Liu J, Li Q, Gu Y, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. *J Biol Chem.* (2009) 284:24006–16. doi: 10.1074/jbc.M109.025528
- XII. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol.* (2007) 8:950–7. doi: 10.1038/ni149